

FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES **(or securities convertible or exchangeable into listed securities)**

Please complete the following:

Name of CNSX Issuer: **Pacific Therapeutics Ltd.** (the "Issuer").

Trading Symbol: **PT**.

Date: Amended **October 1, 2014**.

Is this an updating or amending Notice: **yes**

If yes provide date(s) of prior Notices: **August 5, 2014, September 22, 2014**

Issued and Outstanding Securities of Issuer Prior to Issuance: **37,456,825**

Date of News Release Announcing Private Placement: **August 5, 2014**

Closing Market Price on Day Preceding the Issuance of the News Release: **\$0.05**

1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Jagraj Siduh 7338 Main Street, Vancouver BC V5X 3J5	120,000 units	\$.05	NA	Sect 2.3 of NI 45-106			NA
Douglas Harry Unwin 1500 Ostler Court, Apt 601 North Vancouver, BC V7G 2S2	1,000,000 units	\$.05	NA	Sect 2.5 of NI 45-106	3,917,667		(I)

Brian Gusko 1607 - 1081 Homer Street, Vancouver BC V6B 1M9	200,000 units	\$.05	NA	Sect 2.5 of NI 45-106	190,000		
Hani El Rayess #94 – 904 Lytton St., North Vancouver, BC V7H 2A5	200,000 units	\$.05	NA	Sect 2.5 of NI 45-106	NA		
Interwest Petroleum Ltd. Vancouver, BC	Convertible Note	\$50,000	Converts at a 25% discount to market price subject to CSE rule and securities regulations		Nil	September 11, 2014	N/A

(1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.

(2) Indicate if Related Person.

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: **\$76,000 for the first tranche and up to \$450,000**

2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

If the maximum offering of \$450,000 is fully subscribed, the Company would use up to \$300,000 to complete regulatory applications for a pivotal bio-equivalence study and conduct the study. General & administration expenses and finder's fees would make up the other \$150,000 of the offering. If the offering is not fully subscribed the company will pay finder's fees and general and administration expenses of up to \$150,000 and the rest of the proceeds would go towards the development of PTL-2015. While it is intended that the Company will spend the funds available to it as stated, there may be circumstances where, for sound business reasons, a reallocation of funds may be necessary.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: .

4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities. Description of securities to be issued:

(a) Class **Common Shares**.

(b) Number **1,520,000 for first tranche, and up to 8,000,000 in total**

(c) Price per security **\$0.05**.

(d) Voting rights **Yes**.

5. Provide the following information if Warrants, (options) or other convertible securities are to be issued:

(a) Number **1,520,000 for first tranche, and up to 9,000,000 in total**

(b) Number of securities eligible to be purchased on exercise of Warrants (or options) **1,520,000 for first tranche, and up to 8,000,000 in total**.

(c) Exercise price: **Warrants: \$0.15**.

(d) Expiry Date: **1 year from issue date**

6. Provide the following information if debt securities are to be issued: **Convertible**

Note

- (a) Aggregate principal amount **\$50,000 convertible note**_____.
- (b) Maturity date **1 year from closing**_____.
- (c) Interest rate **1% per month**_____.
- (d) Conversion terms **Convertible into common shares at a 25% discount to market subject to CSE regulations**_____.
- (e) Default provisions **In the case of default, the Creditor may, by written notice to the Pacific Therapeutics Ltd., declare all amounts due and payable, including the principal hereof plus all accrued interest.**

7. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):

- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):_____.
- (b) Cash **NIL for the First tranche -**
- (c) Securities Warrants: _____ **NA**_____
- (d) Other_____.
- (e) Expiry date of any options, warrants etc.
- (f) Exercise price of any options, warrants etc._

8. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship _____

_____.

9. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).

_____.

10. State whether the private placement will result in a change of control.

-
11. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. _____
-

12. Each purchaser has been advised of the applicable securities legislation, restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by Multilateral Instrument 45-102.

2. Acquisition N/A

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: _____
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: _____
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
- (a) Total aggregate consideration in Canadian dollars: _____.
 - (b) Cash: _____.
 - (c) Securities (including options, warrants etc.) and dollar value: _____.
 - (d) Other: _____.
 - (e) Expiry date of options, warrants, etc. if any: _____.
 - (f) Exercise price of options, warrants, etc. if any: _____.
 - (g) Work commitments: _____.

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: _____.
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: _____.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): _____.
 - (b) Cash _____.
 - (c) Securities _____.
 - (d) Other _____.
 - (e) Expiry date of any options, warrants etc. _____.
 - (f) Exercise price of any options, warrants etc. _____.

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. _____

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. _____

_____.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 9 Notice of Private Placement is true.

Dated **October 1, 2014**

Douglas H. Unwin

Name of Director or Senior Officer

/S/ ***"Doug Unwin"*** _

Signature

CEO & President

Official Capacity